Advances in muc1-mediated breast cancer immunotherapy

HIGHLIGHTS

• who: Zhifeng Li et al. from the Currently, CAR, cell therapy is becoming a rapidly developing and extensively used antitumor cell immunotherapy branchAt present, it substantially alters the hematological malignancy landscape, occupying over half of the developing or the already-used cell treatments [118]. However, there were still problems associated with the use of CAR, cells in treating solid tumors, regardless of its successful treatment of hematological cancers [119, ]. Typically, CAR, cell therapy, when it is used in treating solid tumors, is associated with the primary challenge of identifying suitable tumor target antigens with little or no . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.